**Name of Journal:** ***World Journal of*** ***Gastroenterology***

**Manuscript NO: 39929**

**Manuscript Type:** **ORIGINAL ARTICLE**

***Basic Study***

**VSL#3 can prevent ulcerative colitis carcinogenesis in mice**

Wang C *et al*. VSL#3 can prevent ulcerative colitis carcinogenesis

Chunsaier Wang, Wen-Bin Li, Hong-Ying Wang, Yi-Ming Ma, Xin-Hua Zhao, Hong Yang, Jia-Ming Qian, Jing-Nan Li

**Chunsaier Wang, Wen-Bin Li, Hong Yang, Jia-Ming Qian, Jing-Nan Li,** Department of Gastroenterology**,** PUMC Hospital**,** CAMS and PUMC**,** Beijing 100730**,** China

**Hong-Ying Wang, Yi-Ming Ma, Xin-Hua Zhao,** National Cancer Center/Cancer Hospital**,** CAMS and PUMC**,** Beijing 100021**,** China

**ORCID number:** Chunsaier Wang (0000-0002-4410-0834); Wen-Bin Li (0000-0003-0003-9768); Hong-Ying Wang (0000-0001-8443-3839); Yi-Ming Ma (0000-0002-4654-5642); Xin-Hua Zhao (0000-0002-4523-9416); Hong Yang (0000-0002-9475-1256); Jia-Ming Qian (0000-0001-6570-9262); Jing-Nan Li (0000-0002-9578-2580).

**Author contributions:** Wang C and Li WB contributed equally to this work; Li JN Conceived and designed the experiments; Wang C and Li WB Performed the experiments, analyzed and interpreted the data; Wang C and Li JN Drafted the paper and revised it critically for important intellectual content; Wang HY, Ma YM, Zhao XH, Yang H, and Qian JM offered help during the experiments; all authors approved the final version of the manuscript.

**Institutional animal care and use committee statement:** All animal experiments were conducted in accordance with the recommendations of the Animal Care Ethics and Use Committee of Peking Union Medical College Hospital and approved by the same Committee (XHDW-2015-0032).

**Conflict-of-interest statement:** To the best of our knowledge, no conflict of interest exists.

**Data sharing statement:** No additional data are available.

**ARRIVE guidelines statement:** The ARRIVE Guidelines have been adopted.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Correspondence to: Jing-Nan Li, MD, Doctor,** Department of Gastroenterology**,** PUMC Hospital**,** CAMS and PUMC**,** No.1 Shuai Fu Yuan**,** Beijing 100730**,** China. lijn2008@126.com

**Telephone:** 86-10-69155019

**Fax:** 86-10-69155017

**Received:** May 27, 2018

**Peer-review started:** May 27, 2018

**First decision:** July 6, 2018

**Revised:** August 7, 2018

**Accepted:** August 24, 2018

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To investigate the effects of VSL#3 on tumor formation in azoxymethane/dextran sulfate sodium (AOM/DSS) induced mice model and altered fecal and intestinal mucosal microbiota.

***METHODS***

C57BL/6 mice were administered AOM/DSS to develop the ulcerative colitis (UC) carcinogenesis model. The treatment group was gavaged with 5-ASA (75 mg/kg/d), VSL#3 (1.5 × 109 CFU/d), and 5-ASA combined with VSL#3 from the day of AOM injection for 3 mo (5 d/wk), respectively. The tumor load was compared in each group, and tumor necrosis factor (TNF-α) and interleukin (IL)-6 levels evaluated in colon tissue. The stool and intestinal mucosa samples were collected to analyze the differences in the intestinal microbiota by 16s rDNA sequencing method.

***RESULTS***

VSL#3 significantly reduced the tumor load in AOM/DSS-induced mice model and decreased the level of TNF-α and IL-6 in colon tissue. The model group had a lower level of *Lactobacillus* and higher level of *Oscillibacter* and *Lachnoclostridium* in fecal microbiota than the control group. After the intervention with 5-ASA and VSL#3, *Bacillus* and *Lactococcus* were increased, while *Lachnoclostridium* and *Oscillibacter* were reduced. 5-ASA combined with VSL#3 increased the *Lactobacillus* and decreased the *Oscillibacter*. The intestinal mucosal microbiota analysis showed a lower level of *Bifidobacterium* and *Ruminococcaceae*\_UCG-014 and higher level of *Alloprevotella* in the model group as compared to the control group. After supplementation with VSL#3, *Bifidobacterium* was increased. 5-ASA combined with VSL#3 increased the level of both *Lachnoclostridi*um and *Bifidobacterium.*

***CONCLUSION***

VSL#3 can prevent UC carcinogenesis in mice, reduce the colonic mucosal inflammation levels and it is beneficial for rebalancing the fecal and mucosal intestinal microbiota.

**Key words**: Ulcerative colitis carcinogenesis; VSL#3; Tumor necrosis factor-α; Interleukin-6; Intestinal microbiota

**© The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Microbiota and chronic inflammation plays an important role in the procession of ulcerative colitis (UC) carcinogenesis. Our study found VSL#3 could effectively prevent UC carcinogenesis in azoxymethane/dextran sulfate sodium induced mice and decrease the level of tumor necrosis factor-αand IL-6 in colon tissue. The intestinal microbiota dysbiosis exists in UC carcinogenesis. Supplementary VSL#3 is beneficial for rebalancing the fecal and mucosal intestinal microbiota. Based on the data presented here, VSL#3 may be a potential therapeutic agent for UC carcinogenesis prevention.

Wang C, Li WB, Wang HY, Ma YM, Zhao XH, Yang H, Qian JM, and Li JN. VSL#3 can prevent ulcerative colitis carcinogenesis in mice. *World J Gastroenterol* 2018; In press

**INTRODUCTION**

Recently, the incidence of ulcerative colitis (UC) has shown an upward trend, leading to increased clinical attention on UC carcinogenesis. A recent meta-analysis encompassing 8 population-based cohort studies reported a 1.6% prevalence of colorectal cancer (CRC) in patients with UC, and the rate of CRC was 2.4-fold higher than that in the general population[1]. Moreover, the existing treatment for UC is not satisfactory for the prevention of carcinogenesis, involving several risks and side effects with long-term usage; thus, finding new treatment regimens are essential.

Although the etiology of UC is yet to be elucidated, several studies have indicated that the host intestinal microbiota triggers an immune response that is requisite for the onset of the disease[2]. Microbiota also plays a major role in promoting UC carcinogenesis. It downregulates the host immune response, improves the epithelial barrier function, and increases the mucus production[3]. Previous studies demonstrated that in the sterile intestinal environment, *i.e.*, the lack of intestinal microbiota, a significant reduction in carcinogenic mutations and intestinal tumor formation was observed[4]. Chronic inflammation plays a crucial role in UC tumorigenesis *via* cellular DNA damage, telomere shortening, and senescence[5]. Previous studies demonstrated that probiotics exert a superior therapeutic effect on inflammation and UC[6]. VSL#3 is a mixture of *Lactobacillus casei, Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus delbrueckii* subsp. *bulgaricus, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium infantis*,and *Streptococcus salivarius*[7]. It proved to be beneficial in the treatment of UC, including remission and relief of the relapse in mild to moderate diseases[8-10]. Thus, we speculated that probiotic treatment or adjuvant treatment of UC could prevent carcinogenesis. One study demonstrated that VSL#3 can inhibit UC carcinogenesis in mice model[11]; however, the mechanism underlying the VSL#3 treatment of UC carcinogenesis is yet to be elucidated.

Therefore, in the present study, VSL#3 was selected to investigate the effect of prevention on UC carcinogenesis and the differences between fecal and mucosal microbiota analyzed to gain a theoretical insight for the prevention of UC carcinogenesis.

**MATERIALS AND METHODS**

***Animals***

C57BL/6 male mice, 8-wk-old, were purchased from the Vital River Laboratory Animal Technology Co. Ltd. (Beijing, China), housed under 12 h light/dark cycle conditions (temperature 22 ± 1 °C, humidity 40%-60%) in the National Cancer Center/Cancer Hospital animal facilities, and fed a standard diet for the duration of the study. All animal experiments were conducted in accordance with the recommendations of the Animal Care Ethics and Use Committee of Peking Union Medical College Hospital and approved by the same Committee (XHDW-2015-0032).

***Development of UC carcinogenesis model and in vivo treatment***

All mice (*n* = 90) were initially housed together (5 animals/cage) for adaption 1 wk before randomization into five experimental groups: control (*n* = 10), model (*n* = 20), 5-ASA treatment (*n* = 20), VSL#3 treatment (*n* = 20), and 5-ASA + VSL#3 treatment (*n* = 20). In order to establish the UC carcinogenesis model, mice were injected with 12.5 mg/kg body weight (BW) Azoxymethane (AOM) intraperitoneally, and after 1 wk, 2.5% dextran sulfate sodium (DSS) (Mpbio, Solon, OH, United States) was added to their drinking water for 5 d, followed by 10 wk and 2 d of regular drinking water. This modeling method was based on a method described previously with some changes[12]. The three treatment groups including 5-ASA, VSL#3, and 5-ASA+VSL#3 were gavaged 5-ASA (75 mg/kg BW, QD, Ferring Pharmaceuticals Ltd, solubilized in drinking water), VSL#3 (1.5 × 109 CFU/mice, QD, Sigma-Tau Pharmaceuticals Ltd, solubilized in drinking water), and 5-ASA + VSL#3 (75 mg/kg BW + 1.5 × 109 CFU/mice, QD) from the day of AOM injection, respectively. The model group was not subjected to gavage intervention. Also, the control group was neither subjected to modeling nor gavage intervention (Figure 1).

***Specimen collection***

The mice were sacrificed by the 12th week *via* transcardiac perfusion, and colon tissues were removed. The colons were slitted longitudinally along the main axis and washed with 0.9% saline. The long and short diameter of each tumor was measured using sliding calipers, and then, the total tumor load of each colon was calculated (sum of the product of long and short diameter of each tumor). Subsequently, the whole colon was divided into 4 sections. The section near the anus washed with 0.9% saline to remove the non-adherent bacteria were flash-frozen in liquid nitrogen and stored at -80 °C for subsequent microbiota analysis. The remaining sections were used for enzyme-linked immunosorbent assays**(**ELISA) and histopathological examinations, respectively. A stool sample was collected just before AOM injection and sacrifice, respectively. A total of 6 mice were randomly selected from each group, and their stool and intestinal mucosa samples were sent to Allwegene (Beijing, China) for analyzing the differences in intestinal microbiota by 16S rDNA sequencing method.

***Fecal DNA extraction and pyrosequencing***

Microbial genomic DNA was isolated using a QIAamp DNA Micro Kit according to the manufacturer’s instructions. The final quantity and quality of the DNA were assessed at 260 and 280 nm using an ultraviolet spectrophotometer and stored at -20 °C before further analysis. The V3-V4 hypervariable regions of the 16S rDNA gene were subjected to high-throughput sequencing by Allwegene using the Illumina Miseq PE300 sequencing platform (Illumina Inc., CA, United States).

***ELISA for tumor necrosis factor-α and interleukin-6 in colon mucosa***

The levels of tumor necrosis factor (TNF)-α and interleukin (IL)-6 in the colon mucosa are measured using commercial mouse TNF-α and IL-6 ELISA Kits (eBioscience, United States), according to the manufacturer’s protocols, respectively. The absorbance is measured at 450 nm. The results were expressed as pg/mg tissue. A total of 8 mice were selected randomly from each group for ELISA.

***Statistical analysis***

Data are presented as mean ± SE. All statistical analyses were performed using GraphPad Prism Software Version 6.0 (GraphPad Software Inc., La Jolla, CA, United States). Statistical differences between experimental variants were assessed by two-tailed independent *t*-test, and data from more than two groups were analyzed by one-way ANOVA. Anosim and metastats analysis were used for microbiota analysis. *P* < 0.05 was considered as statistical significance.

**RESULTS**

***General health of mice in each group***

As shown in Figure 2, compared to the control mice, the BW loss was significantly higher in mice treated with AOM/DSS after day 10 of DSS administration, which was accompanied by colitis symptoms, such as loose and bloody stool and dim body hair, fatigue, and less movement. These symptoms were alleviated when the mice received ordinary drinking water. In week 9, some mice treated with AOM/DSS presented bloody stool again, as well as, anal prolapse in week 10. However, no apparent weight loss was observed in the control mice, and no significant differences were detected among the five groups at the end of week 12.

***Establishment of UC carcinogenesis mice model***

The mice were sacrificed by week 12, and the colorectal tumors were observed in the model and treated groups (5-ASA, VSL#3, and 5-ASA + VSL#3 group). Strikingly, the tumor was primarily localized in the distal two-thirds of the colon. Anal tumor fusion and ring growth at the end of the rectum were observed in mice with anal prolapse (Figure 3). The pathological analysis showed that mucosal carcinoma or high-grade intraepithelial neoplasia observed in mice treated with AOM/DSS; these were manifested with colonic gland structure disorders, large nuclear, deep staining, and the decreased nucleoplasmic ratio (Figure 4).

***Effects of VSL#3 on UC carcinogenesis***

Treatment with AOM and DSS led to 100% (19/19, one mouse died during the experiment due to fighting) incidence of colonic neoplasms in the model group with the mean tumor load of 0.97 ± 0.19 cm. 5-ASA and VSL#3 administration significantly reduced both the tumor formation rate and the tumor load (Table 1 and Figure 5). Furthermore, no colonic tumor was detected in the control group.

***Colonic TNF-α and IL-6 level comparison***

As illustrated in Figure 6 and Tables 2 and 3, the levels of colonic tissue TNF-α and IL-6 in the model group were significantly higher than that in the control group. The increased levels of these inflammatory factors induced by AOM/DSS were attenuated by 5-ASA and VSL#3 treatment.

***VSL#3 treatment alters the composition of fecal microbiota in AOM/DSS treated mice***

In order to characterize the diversity of fecal-associated community in UC carcinogenesis, we used Chao 1 and the observed species indexes, as well as the Shannon and Simpson indexes. No significant difference was detected in the diversity and composition of fecal microbiota in each group at the beginning of the experiment. After the 12-wk experiment, although no statistically significant difference was detected in the diversity among groups, the microbiota composition was altered considerably. The change in the composition of fecal microbiota induced by AOM/DSS administration was characterized by a decrease in *Lactobacillus* coupled with an increase in *Oscillibacter* and *Lachnoclostridium* as indicated by metastats analysis (*P* < 0.05). Both 5-ASA and VSL#3 supplementation was associated with a significant increase in *Bacillus* and *Lactococcus* and a decrease in *Oscillibacter* and *Lachnoclostridium* as compared to the model group (*P* < 0.05). 5-ASA combined with VSL#3 increased the level of *Lactobacillus* and decreased that of *Oscillibacter* (*P* < 0.05) (Table 4).

***VSL#3 treatment alters the composition of mucosal microbiota in AOM/DSS treated mice.***

For the mucosal microbiota, no difference was observed in the community diversity among the groups after the 12-wk experiment. However, the distinct shift in the microbiota composition was observed by PCA and Anosim analysis (R > 0, *P* < 0.05). Further investigation into the discrete bacterial taxa revealed that *Ruminococcaceae* UCG-014 and *Bifidobacterium* decreased, while *Alloprevotella* increased in the model group than in the control group. After supplementation with VSL#3, *Bifidobacterium* was increased. Although 5-ASA alone did not alter the mucosal microbiota, the combination with VSL#3 increased *Lachnoclostridium* and *Bifidobacterium* in the mucosa (Table 5).

**DISCUSSION**

The current study found that the rate of tumor formation and tumor load of VSL#3 group were significantly lower than those of the model group, while the levels of TNF-α and IL-6 in the colon tissue in the model group were significantly higher than the control group. After the intervention of 12 wk, the increase in TNF-α and IL-6 caused by AOM/DSS declined significantly by VSL#3. These findings were consistent with that of the previous studies[11,13,14]. The major risk of long-term chronic inflammation is tumor occurrence[2]. Thus, we speculated that VSL#3 could prevent UC carcinogenesis by inhibiting the inflammatory response.

Herein, we found differences between the fecal and mucosal microbiota. In the case of fecal microbiota, the model group mice possessed less *Lactobacillus* and more Oscillibacter and Lachnoclostridium as compared to the control group. Previous studies have shown that *Lactobacillus bulgaricus* can reduce colitis[15], and *Lactobacillus rhamnosus* can effectively maintain the UC remission[16]. *Oscillibacter* and *Lachnoclostridium* are newly discovered genus with respect to the digestive diseases. In the case of mucosal microbiota, the genus UCG-014 of *Ruminococcaceae* and the level of *Bifidobacterium* decreased, while that of *Alloprevotella* increased in the model group as compared to the control group. Some genus of *Ruminococcaceae* can consume hydrogen to produce acetate, which is subsequently used by *Roseburia* to produce butyrate that is not only the main source of energy for intestinal epithelial cells but can also inhibit the signaling pathway of proinflammatory cytokines[17]. *Bifidobacterium* can produce bacteriocin and organic acids against pathogens on intestinal mucosal invasion[18]. It regulates the intestinal mucosal immunity and prevents the colonization of pathogens. The role of *Alloprevotella* is not yet clarified as it is not reported frequently in the digestive disease. Therefore, we hypothesize that dysbiosis occurs during UC carcinogenesis, which reduces the beneficial genus and increases the detrimental types.

Previous studies have shown that supplementation of probiotics can balance the intestinal microbiota of UC patients[6], which led us to speculate that supplementation of probiotics can also balance the intestinal microbiota of UC-associated carcinogenesis. The current study demonstrated that *Bacillus* and *Lactococcus* were increased, while *Oscillibacter* and *Lachnoclostridium* were decreased in the feces following VSL#3 treatment as compared to the model group. Some species of *Bacillus* and *Lactococcus* are widely used as probiotics. For example, *Bacillus subtilis* can significantly reduce DSS-induced colonic mucosal injury and inflammatory factors in mice and improve the levels of short-chain fatty acids[19]. *Lactococcus* lactis exerts a protective effect on DSS-induced colitis model mice[20].

Furthermore, *Bifidobacterium* increased in the mucosa after VSL#3 supplementation, thereby suggesting that VSL#3 supplementation, following the onset of AOM/DSS-induced colitis, promotes a healthy gastrointestinal bacterial community. Interestingly, VSL#3 is composed of 8 strains, including 1 of *Streptococcus*, 3 of *Bifidobacterium*, and 4 of *Lactobacillus*. However, none of the above strains increased significantly in the fecal intestinal microbiota after 3-mo gavage, suggesting that the positive effect of probiotics on the intestinal microbiota of the host is by regulating the proportion of beneficial and harmful bacteria.

For the differences between fecal and mucosal microbiota, we make the following explanation. There are 3 kinds of Bifidobacterium in VSL#3, and Bifidobacterium just increased in mucosal microbiota but not in fecal. This phenomenon indicated that Bifidobacterium is easily colonized in the mucosa. Conversely, *Bacillus* and *Lactococcus* increased in fecal microbiota after VSL#3 intervention but not in the mucosa, indicating that *Bacillus* and *Lactococcus* can colonize easily in the feces. Strikingly, the 4 types of *Lactobacillus* in VSL#3 group did not increase either in the fecal or mucosal microbiota, thereby suggesting that the intestinal environment of UC carcinogenesis is not optimal for the growth of *Lactobacillus*. Only in 5-ASA combined with VSL#3 group, the increase in *Lactobacillus* was observed in feces, which might be attributed to the low luminal pH. However, these hypotheses necessitate further studies for substantiation.

5-ASA is the first-line treatment for mild-to-moderate UC, and studies have found that 5-ASA ≥ 1.2 g/d could reduce the risk of carcinogenesis in patients with mild-to-moderate UC[21]. Thus, considering the clinical significance, we designed the 5-ASA monotherapy group and the 5-ASA combined with VSL#3 group. Interestingly, the change in the fecal microbiota in the 5-ASA group was similar to that in the VSL#3 monotherapy group. The potential mechanisms regulating the microbiota by 5-ASA are as follows: (1) Change in the colonic luminal pH: 5-ASA is released in the colon and translated into acetylsalicylic acid, which in turn, can decrease the luminal pH[22]; low luminal pH is optimal for the growth of *Bifidobacteria* and *Lactobacilli*[23]; (2) improvement in the anoxia environment: 5-ASA can inhibit the production of chemotactic eicosanoids and cyclooxygenase 2 (COX2), which induces anoxia and can inactivate the oxygen-derived free radicals, improving the anoxia situation, which might affect the composition of intestinal microbiota[22]; and (3) 5-ASA can downregulate the expression of genes that are involved in bacterial metabolism, invasiveness, and antibiotic/stress resistance[24].

Nevertheless, the present study has some limitations. Herein, we only observed the phenomenon of gut microbiota changes, while the specific role of flora is yet to be explored. Our future *in vitro* studies would focus on the underlying mechanisms.

In conclusions, the current study demonstrated that VSL#3 prevented UC carcinogenesis in AOM/DSS-induced mice model and decreased the level of TNF-α and IL-6 in colon tissue. The intestinal microbiota dysbiosis was exhibited in UC carcinogenesis mice. Supplementary VSL#3 was beneficial for a balanced fecal and mucosal microbiota in UC carcinogenesis mice. Taken together, VSL#3 may serve as a potential therapeutic agent for the prevention of UC carcinogenesis. Ongoing studies in our group are focused on the underlying mechanisms.

**ARTICLE HIGHLIGHTS**

***Research background***

Recently, an upward trend shown in the incidence of ulcerative colitis (UC), which leading to increased clinical attention on UC carcinogenesis.

***Research motivation***

It is not satisfactory that the existing treatment for UC in the prevention of carcinogenesis, involving several risks and side effects with long-term usage; thus, finding new treatment regimens are essential.

***Research objectives***

To investigate the effects of VSL#3 on tumor formation in azoxymethane/dextran sulfate sodium (AOM/DSS) induced mice model, and altered fecal and intestinal mucosal microbiota.

***Research methods***

C57BL/6 mice were administered AOM/DSS to develop the ulcerative colitis UC carcinogenesis model. The treatment group was gavaged with 5-ASA (75 mg/kg/d), VSL#3 (1.5 × 109 CFU/d), and 5-ASA combined with VSL#3 from the day of AOM injection for 3 mo (5 d/wk), respectively. The tumor load was compared in each group, and tumor necrosis factor (TNF-α) and interleukin (IL)-6 levels evaluated in colon tissue. The stool and intestinal mucosa samples were collected to analyze the differences in the intestinal microbiota by 16s rDNA sequencing method.

***Research results***

VSL#3 significantly reduced the tumor load in AOM/DSS-induced mice model, and decreased the level of TNF-α and IL-6 in colon tissue. The model group had a lower level of *Lactobacillus* and higher level of *Oscillibacter* and *Lachnoclostridium* in fecal microbiota than the control group. *Bacillus* and *Lactococcus* were increased after the intervention with 5-ASA and VSL#3, while *Lachnoclostridium* and *Oscillibacter* were reduced. 5-ASA combined with VSL#3 increased the *Lactobacillus* and decreased the *Oscillibacter*. The intestinal mucosal microbiota analysis showed a lower level of *Bifidobacterium* and *Ruminococcaceae*\_UCG-014 and higher level of *Alloprevotella* in the model group as compared to the control group. *Bifidobacterium* was increased after supplementation with VSL#3. 5-ASA combined with VSL#3 increased the level of both *Lachnoclostridi*um and *Bifidobacterium.*

***Research conclusions***

In mice, VSL#3 can prevent UC carcinogenesis, reduce the colonic mucosal inflammation levels, and is beneficial for rebalancing the fecal and mucosal intestinal microbiota.

***Research perspectives***

VSL#3 may be a potential therapeutic agent for UC carcinogenesis prevention based on the data presented here.

**ACKNOWLEDGMENTS**

We thank the staff at theNational Cancer Center/Cancer Hospital of the Chinese Academy of Medical Sciences and Peking Union Medical College.

**REFERENCES**

1 **Jess T**, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. *Clin Gastroenterol Hepatol* 2012; **10**: 639-645 [PMID: 22289873 DOI: 10.1016/j.cgh.2012.01.010]

2 **Uronis JM**, Mühlbauer M, Herfarth HH, Rubinas TC, Jones GS, Jobin C. Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. *PLoS One* 2009; **4**: e6026 [PMID: 19551144 DOI: 10.1371/journal.pone.0006026]

3 **Derikx LA**, Dieleman LA, Hoentjen F. Probiotics and prebiotics in ulcerative colitis. *Best Pract Res Clin Gastroenterol* 2016; **30**: 55-71 [PMID: 27048897 DOI: 10.1016/j.bpg.2016.02.005]

4 **Rakoff-Nahoum S**, Medzhitov R. Role of toll-like receptors in tissue repair and tumorigenesis. *Biochemistry* (Mosc) 2008; **73**: 555-561 [PMID: 18605980]

5 **Risques RA**, Lai LA, Himmetoglu C, Ebaee A, Li L, Feng Z, Bronner MP, Al-Lahham B, Kowdley KV, Lindor KD, Rabinovitch PS, Brentnall TA. Ulcerative colitis-associated colorectal cancer arises in a field of short telomeres, senescence, and inflammation. *Cancer Res* 2011; **71**: 1669-1679 [PMID: 21363920 DOI: 10.1158/0008-5472.CAN-10-1966]

6 **Verna EC**, Lucak S. Use of probiotics in gastrointestinal disorders: what to recommend? *Therap Adv Gastroenterol* 2010; **3**: 307-319 [PMID: 21180611 DOI: 10.1177/1756283X10373814]

7 **Liang J**, Sha SM, Wu KC. Role of the intestinal microbiota and fecal transplantation in inflammatory bowel diseases. *J Dig Dis* 2014; **15**: 641-646 [PMID: 25389085 DOI: 10.1111/1751-2980.12211]

8 **Shen J**, Zuo ZX, Mao AP. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials. *Inflamm Bowel Dis* 2014; **20**: 21-35 [PMID: 24280877 DOI: 10.1097/01.MIB.0000437495.30052.be]

9 **Sood A**, Midha V, Makharia GK, Ahuja V, Singal D, Goswami P, Tandon RK. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. *Clin Gastroenterol Hepatol* 2009; **7**: 1202-1209, 1209.e1 [PMID: 19631292 DOI: 10.1016/j.cgh.2009.07.016]

10 **Tursi A**, Brandimarte G, Papa A, Giglio A, Elisei W, Giorgetti GM, Forti G, Morini S, Hassan C, Pistoia MA, Modeo ME, Rodino' S, D'Amico T, Sebkova L, Sacca' N, Di Giulio E, Luzza F, Imeneo M, Larussa T, Di Rosa S, Annese V, Danese S, Gasbarrini A. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. *Am J Gastroenterol* 2010; **105**: 2218-2227 [PMID: 20517305 DOI: 10.1038/ajg.2010.218]

11 **Talero E**, Bolivar S, Ávila-Román J, Alcaide A, Fiorucci S, Motilva V. Inhibition of chronic ulcerative colitis-associated adenocarcinoma development in mice by VSL#3. *Inflamm Bowel Dis* 2015; **21**: 1027-1037 [PMID: 25793324 DOI: 10.1097/MIB.0000000000000346]

12 **Tanaka T**, Kohno H, Suzuki R, Yamada Y, Sugie S, Mori H. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. *Cancer Sci* 2003; **94**: 965-973 [PMID: 14611673]

13 **Bromberg J**, Wang TC. Inflammation and cancer: IL-6 and STAT3 complete the link. *Cancer Cell* 2009; **15**: 79-80 [PMID: 19185839 DOI: 10.1016/j.ccr.2009.01.009]

14 **Bassaganya-Riera J**, Viladomiu M, Pedragosa M, De Simone C, Hontecillas R. Immunoregulatory mechanisms underlying prevention of colitis-associated colorectal cancer by probiotic bacteria. *PLoS One* 2012; **7**: e34676 [PMID: 22511958 DOI: 10.1371/journal.pone.0034676]

15 **Takamura T**, Harama D, Fukumoto S, Nakamura Y, Shimokawa N, Ishimaru K, Ikegami S, Makino S, Kitamura M, Nakao A. Lactobacillus bulgaricus OLL1181 activates the aryl hydrocarbon receptor pathway and inhibits colitis. *Immunol Cell Biol* 2011; **89**: 817-822 [PMID: 21321579 DOI: 10.1038/icb.2010.165]

16 **Zocco MA**, dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, Novi M, Rigante D, Cazzato IA, Ojetti V, Armuzzi A, Gasbarrini G, Gasbarrini A. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. *Aliment Pharmacol Ther* 2006; **23**: 1567-1574 [PMID: 16696804 DOI: 10.1111/j.1365-2036.2006.02927.x]

17 **Morgan XC**, Tickle TL, Sokol H, Gevers D, Devaney KL, Ward DV, Reyes JA, Shah SA, LeLeiko N, Snapper SB, Bousvaros A, Korzenik J, Sands BE, Xavier RJ, Huttenhower C. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. *Genome Biol* 2012; **13**: R79 [PMID: 23013615 DOI: 10.1186/gb-2012-13-9-r79]

18 **Zhiwei L**, Xuequn W, tiantian L. The clinical significance of intestinal flora changes in patients with ulcerative colitis. *Chin J Gastroenterol Hepatol* 2016; **25**: 554-556

19 **Zhang HL**, Li WS, Xu DN, Zheng WW, Liu Y, Chen J, Qiu ZB, Dorfman RG, Zhang J, Liu J. Mucosa-reparing and microbiota-balancing therapeutic effect of Bacillus subtilis alleviates dextrate sulfate sodium-induced ulcerative colitis in mice. *Exp Ther Med* 2016; **12**: 2554-2562 [PMID: 27698758 DOI: 10.3892/etm.2016.3686]

20 **Berlec A**, Perše M, Ravnikar M, Lunder M, Erman A, Cerar A, Štrukelj B. Dextran sulphate sodium colitis in C57BL/6J mice is alleviated by Lactococcus lactis and worsened by the neutralization of Tumor necrosis Factor α. *Int Immunopharmacol* 2017; **43**: 219-226 [PMID: 28039805 DOI: 10.1016/j.intimp.2016.12.027]

21 **Zhao LN**, Li JY, Yu T, Chen GC, Yuan YH, Chen QK. 5-Aminosalicylates reduce the risk of colorectal neoplasia in patients with ulcerative colitis: an updated meta-analysis. *PLoS One* 2014; **9**: e94208 [PMID: 24710620 DOI: 10.1371/journal.pone.0094208]

22 **Xue L**, Huang Z, Zhou X, Chen W. The possible effects of mesalazine on the intestinal microbiota. *Aliment Pharmacol Ther* 2012; **36**: 813-814 [PMID: 22984958 DOI: 10.1111/apt.12034]

23 **Kerr BJ**, Weber TE, Ziemer CJ, Spence C, Cotta MA, Whitehead TR. Effect of dietary inorganic sulfur level on growth performance, fecal composition, and measures of inflammation and sulfate-reducing bacteria in the intestine of growing pigs. *J Anim Sci* 2011; **89**: 426-437 [PMID: 20952529 DOI: 10.2527/jas.2010-3228]

24 **Kaufman J**, Griffiths TA, Surette MG, Ness S, Rioux KP. Effects of mesalamine (5-aminosalicylic acid) on bacterial gene expression. *Inflamm Bowel Dis* 2009; **15**: 985-996 [PMID: 19202572 DOI: 10.1002/ibd.20876]

**P-Reviewer:** Gardlik R, Suzuki H **S-Editor:** Wang XJ

**L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** China

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

******

**Figure 1 Experimental protocol for ulcerative colitis carcinogenesis model and treatment.**

******

**Figure 2 Body weight in each group.**

******

**Figure 3 Representative image of colonic tumor in each group that was examined under naked eye.**

******

**Figure 4 Representative image of hematoxylin-eosin staining of colon tissue examined under a microscope (40 × 100 ×).** A: Control group, the colonic mucosa glands were normal in the control group, the structure was regular, and the opening was good; B: Model group, the colonic gland structure presented disorders, large nucleus, deep staining, and decreased nucleoplasmic ratio.



**Figure 5 Tumor load in each group.**



**Figure 6 Colonic tumor necrosis factor-α** **and interleukin-6 levels in different groups.** a*P* < 0.05, b*P* < 0.01, c*P* < 0.001. TNF-α: Tumor necrosis factor-α; IL-6: Interleukin-6.

**Table 1 Tumor formation rate and tumor load in each group**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Group** | ***n*** | **Tumor formation rate (%)** | **Tumor load (cm)** | ***P-*value(*vs* model group)** |
| 5-ASA | 20 | 65 (13/20) | 0.43 ± 0.14 | 0.0269 |
| VSL#3 | 20 | 65 (13/20) | 0.25 ± 0.07 | 0.0009 |
| 5-ASA + VSL#3 | 19 | 63.2 (12/19) | 0.46 ± 0.11 | 0.0261 |
| Model | 19 | 100 (19/19) | 0.97 ± 0.19 | - |
| Control | 10 | 0 | 0 | - |

**Table 2 Level of tumor necrosis factor-α in colon tissue in each group**

|  |  |  |  |
| --- | --- | --- | --- |
| **Group**  | ***n*** | **TNF-α (pg/mg tissue)** | ***P*-value (*vs* model group)** |
| 5-ASA | 8 | 14.66 ± 0.72 | < 0.05 |
| VSL#3 | 8 | 25.89 ± 5.25 | < 0.05 |
| 5-ASA + VSL#3 | 8 | 21.33 ± 4.55 | < 0.05 |
| Model  | 8 | 68.38 ± 18.73 | - |
| Control | 8 | 10.49 ± 0.30 | < 0.01 |

**Table 3 Level of interleukin-6 in colon tissue in each group**

|  |  |  |  |
| --- | --- | --- | --- |
| **Group** | ***n*** | **IL-6 (pg/mg tissue)** | ***P*-value (*vs* model group)** |
| 5-ASA | 8 | 28.19 ± 6.80 | < 0.0001 |
| VSL#3 | 8 | 99.71 ± 31.14 | < 0.05 |
| 5-ASA+VSL#3 | 8 | 81.43 ± 26.98 | < 0.01 |
| Model  | 8 | 254.2 ± 32.49 | - |
| Control | 8 | 25.47 ± 5.50 | < 0.0001 |

**Table 4 Comparison of fecal microbiota (abundance)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Genus** | **Control (%)** | **Model (%)** | **5-ASA (%)** | **VSL2 (%)** | **5-ASA +** VSL#3 **(%)** |
| *Lactobacillus* | 4.77 | 3.261 | 2.65 | 4.06 | 9.864 |
| *Oscillibacter* | 0.64 | 1.301 | 0.542 | 0.523 | 0.794 |
| *Lachnoclostridium* | 0.45 | 1.191 | 0.482 | 0.393 | 1.08 |
| *Bacillus* | 1.01 | 0.98 | 24.002 | 23.343 | 0.66 |
| *Lactococcus* | 2.3 | 2.29 | 8.582 | 7.863 | 1.59 |

1Statistically significant (*P* < 0.05) between the model and control groups; 2Statistically significant (*P* < 0.05) between the model and 5-ASA groups; 3Statistically significant (*P* < 0.05) between the model and VSL#3 groups; 4Statistically significant (*P* < 0.05) between the model and 5-ASA + VSL#3 groups.

**Table 5 Comparison of mucosal microbiota (abundance)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Genus** | **Control (%)** | **Model (%)** | **5-ASA(%)** | **VSL#3 (%)** | **5-ASA + VSL#3 (%)** |
| *Alloprevotella* | 0.26 | 1.571 | 1.16 | 0.95 | 1.22 |
| *Ruminococcaceae*\_UCG-014 | 6.63 | 1.491 | 1.64 | 1.5 | 1.15 |
| *Bifidobacterium* | 3.45 | 0.241 | 0.19 | 3.342 | 1.903 |
| *Lachnoclostridium* | 0.24 | 0.4 | 2.05 | 0.25 | 2.033 |

1Statistically significant (*P* < 0.05) between the model and the control groups; 2Statistically significant (*P* < 0.05) between the model and the VSL#3 groups; 3Statistically significant (*P* < 0.05) between the model and the 5-ASA + VSL#3 groups.